Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Winners and Losers of New PMP Criteria: Januvia Earns 1st Premium while Xarelto, Humira Miss It
March 6, 2018
- Annual Savings from Use of Biosimilars Stands at Just 8.7 Billion Yen: MHLW
March 6, 2018
- Hemophilia A Treatment Hemlibra, Zoster Vaccine Shingrix Clear MHLW Panel
March 5, 2018
- One-Time Blockbusters to Be Re-Priced at 2.5-Times Gx Price Average; Mevalotin, Takepron among the List
March 5, 2018
- Repatha Gets Price Raise as It Wins Post-Launch Premium for CV Risk Reduction
March 5, 2018
- 314 APIs Eligible for Price Maintenance Premium in FY2018, Down from 416
March 5, 2018
- Opdivo Faces 23.8% Price Cut as Slew of Reduction Rules Apply; Nexium Down 16.1% on Huge Seller Slash
March 5, 2018
- MHLW Unveils New List Prices, Post-Launch Foreign Price Adjustment Applied Only to Opdivo
March 5, 2018
- MHLW Panel Backs Nobelpharma’s Sirolimus Gel, Azilect, Januvia-Suglat Combo and More
March 2, 2018
- Enforcement Regulations of Clinical Research Law Promulgated
March 2, 2018
- Junior LDP Lawmakers Question Drug Pricing: Fiscal Structure Panel
March 1, 2018
- MHLW Still Pondering Steps to Ensure Proper Sales Activities by Drug Reps
February 28, 2018
- MHLW Weighs Amendment to PMD Law as It Looks Beyond 2025: Bureau Chief
February 28, 2018
- Japan Approves 23 NMEs in 2017, Lowest in Past 5 Years
February 28, 2018
- PMDA to Take Applications for Using MID-NET Starting April 1
February 27, 2018
- Clinical Research Law to Take Effect on April 1
February 26, 2018
- Shionogi’s Single-Dose Flu Med Gets Accelerated OK
February 26, 2018
- Darzalex, Somatuline Grab Orphan Status for New Indications
February 23, 2018
- PMDA Announces Procedures for Using MID-NET
February 21, 2018
- Turning Point for Blood Products? Discussions on Basic Policy on Blood Law Moving Ahead
February 20, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…